eClinical Technology and Industy News

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

Excerpt from the Press Release:

LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of the action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.

The lead collaborator is Takashi Mitsui MD, Ph.D., professor and the chair of the Department of Laboratory Medicine, a known leading expert on lipid metabolism who specializes in dyslipidemia and metabolic syndrome.

Kazuko Matsuda, MD, Ph.D., MPH, Chief Medical Officer of MediciNova, Inc, commented, “MN 001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrotic and anti-inflammatory effects have been observed in multiple animal models studies. It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously. In the phase 2 trial in NASH/NAFLD patients with hypertriglyceridemia, MN-001 (tipelukast) reduced serum triglycerides, increased high-density lipoproteins (HDL-C), and reduced low-density lipoproteins (LDL) during the 12-week treatment period. Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes. We believe this research collaboration will provide new insights into the mechanism of action of MN-001 in the lipid metabolism and metabolic syndrome field and identify the conditions that would benefit from MN-001 treatment.”

About MN-001 (tipelukast)

MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO).

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?